China channel feed

No­var­tis’ CAR-T part­ner in Chi­na wraps $383M take-pri­vate deal en­gi­neered by CEO

5 years ago
Deals
Cell/Gene Tx

Per­cep­tive births its first in-house start­up — and it's a Chi­na play

5 years ago
Startups
Deals

CAR-T fil­ing in sight, Frank Zhang grabs full con­trol of J&J-part­nered Leg­end Biotech, steps down from Gen­Script

5 years ago
People

FBI crack­down on Chi­na’s R&D es­pi­onage in­ten­si­fies with new ar­rests and one fugi­tive in San Fran­cis­co

5 years ago

Hous­ton’s huge R&D hub takes cen­ter stage in feds’ cam­paign to clip Chi­na’s ties to re­searchers, IP theft

5 years ago

Jus­tice De­part­ment ac­cus­es Chi­nese hack­ers of tar­get­ing US biotechs in a cy­bertheft cam­paign aimed at steal­ing Covid-19 R&D se­crets

5 years ago
Coronavirus

Juno/WuX­i's cell ther­a­py ven­ture buys out sol­id tu­mor play­er in Chi­na, gain­ing a dis­cov­ery en­gine and por­tend­ing more M&A to come

5 years ago
Deals
Cell/Gene Tx

Chi­na's CRO pow­er­house Tigermed to seek $1B IPO in Hong Kong — re­port

5 years ago
Financing

Chi­na's BeiGene now has $5B+ cash in its cof­fers. How's the Am­gen-part­nered biotech go­ing to spend it?

5 years ago

Oph­thalmic drugs, can­cer cell ther­a­pies at­tract $340M+ on two HKEX biotech de­buts

6 years ago
Financing

Look­ing for 'ex­ter­nal in­no­va­tion,' Boehringer In­gel­heim re­serves $500M+ for new Shang­hai hub

6 years ago

Meet the lat­est ge­nom­ic da­ta com­pa­ny — aka WuXi NextCODE with­out the Chi­na op­er­a­tions

6 years ago
Outsourcing

Chi­nese vac­cine de­vel­op­ers have be­gun to shed some se­cre­cy around Covid-19 can­di­dates. What do we know?

6 years ago
Coronavirus
In Focus

It's not just Charles Lieber: NI­H's on­go­ing in­ves­ti­ga­tion has swept up 54 sci­en­tists who vi­o­lat­ed rules about for­eign ties

6 years ago

A sto­ried Chi­nese phar­ma part­ner of Bris­tol My­ers, Am­gen — and avid biotech sup­port­er — plots HK IPO

6 years ago
Financing

Juno, WuXi JV in Chi­na score $100M in fresh fund­ing as it sets stage for first CAR-T ap­proval

6 years ago
Financing
Cell/Gene Tx

Sanofi sharp­ens fo­cus on bis­pecifics, and Chi­na, with Al­pham­ab deal

6 years ago
Deals

Har­vard's Charles Lieber in­dict­ed for ly­ing to the feds, bring­ing US re­searcher­s' Chi­na ties back to the spot­light

6 years ago
People

Lil­ly, In­cyte-al­lied Chi­nese drug­mak­er In­novent bags Roche as part­ner in deal that could yield bil­lions

6 years ago
Deals
Cell/Gene Tx

RA Cap­i­tal, Hill­house join $310M rush to back Ever­est's climb to com­mer­cial heights in Chi­na

6 years ago
Financing

Hill­house re­casts spot­light on Chi­na's biotech scene with $160M round for Shang­hai-based an­ti­body mak­er

6 years ago
Financing

The big mon­ey: Poised to make drug R&D his­to­ry, a Chi­na biotech un­veils uni­corn rac­ing am­bi­tions in a bid to raise $350M-plus on Nas­daq

6 years ago
Financing

As tislelizum­ab gains trac­tion in Chi­na, BeiGene pulls the cur­tain on NSCLC da­ta sup­port­ing the PD-1 drug

6 years ago
R&D

Two years in, Hong Kong’s biotech ex­per­i­ment has been val­i­dat­ed

6 years ago
Financing
Biotech Voices
First page Previous page 16171819202122 Next page Last page
A service from the Financial Times